Cargando…
Cyclocreatine Suppresses Creatine Metabolism and Impairs Prostate Cancer Progression
Prostate cancer is the second most common cause of cancer mortality in men worldwide. Applying a novel genetically engineered mouse model (GEMM) of aggressive prostate cancer driven by deficiency of the tumor suppressors PTEN and Sprouty2 (SPRY2), we identified enhanced creatine metabolism as a cent...
Autores principales: | Patel, Rachana, Ford, Catriona A., Rodgers, Lisa, Rushworth, Linda K., Fleming, Janis, Mui, Ernest, Zhang, Tong, Watson, David, Lynch, Victoria, Mackay, Gillian, Sumpton, David, Sansom, Owen J., Vande Voorde, Johan, Leung, Hing Y. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381098/ https://www.ncbi.nlm.nih.gov/pubmed/35675421 http://dx.doi.org/10.1158/0008-5472.CAN-21-1301 |
Ejemplares similares
-
Phosphocyclocreatine is the dominant form of cyclocreatine in control and creatine transporter deficiency patient fibroblasts
por: Gorshkov, Kirill, et al.
Publicado: (2019) -
Cyclocreatine treatment ameliorates the cognitive, autistic and epileptic phenotype in a mouse model of Creatine Transporter Deficiency
por: Cacciante, Francesco, et al.
Publicado: (2020) -
PPAR-gamma induced AKT3 expression increases levels of mitochondrial biogenesis driving prostate cancer
por: Galbraith, Laura C. A., et al.
Publicado: (2021) -
Creatine and cyclocreatine treatment of human colon adenocarcinoma xenografts: (31)P and (1)H magnetic resonance spectroscopic studies
por: Kristensen, C A, et al.
Publicado: (1999) -
Sprouty2 loss‐induced IL6 drives castration‐resistant prostate cancer through scavenger receptor B1
por: Patel, Rachana, et al.
Publicado: (2018)